Alpelisib, CAS [[1217486-61-7]]

Produktübersicht

• Artikelname: Alpelisib, CAS [[1217486-61-7]]
• Artikelnummer: MCE-HY-15244
• Hersteller Artikelnummer: HY-15244
• Alternativnummer: MCE-HY-15244-1G,MCE-HY-15244-5MG,MCE-HY-15244-10MG,MCE-HY-15244-50MG,MCE-HY-15244-100MG,MCE-HY-15244-200MG,MCE-HY-15244-10MMX1ML,MCE-HY-15244-500MG
• Hersteller: MedchemExpress
• Kategorie: Biochemikalien
• Alternative Synonym: BYL-719

Produktbeschreibung

Alpelisib (BYL-719) is an orally active PI3Kalpha-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence, it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3beta/beta-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome[1][2][3][4].

Produkteigenschaften

• Molekulargewicht: 441.47
• Reinheit: 99.95
• CAS Nummer: [1217486-61-7]
• Formel: C19H22F3N5O2S
• Target-Kategorie: Apoptosis,PI3K

Anwendungsbeschreibung

• Anwendungsbeschreibung: MCE Product type: Reference compound